You are here: Home » 2021 » November » Archives for 4th

Resverlogix Enters into a Cooperation Agreement with the Supreme Council of the Arab-African Economy to Support the Development of Apabetalone for COVID-19 Patients

CALGARY, Alberta, Nov. 04, 2021 (GLOBE NEWSWIRE) — Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX), a world leader in epigenetics or gene regulation, is pleased to announce today that it has entered into a cooperation agreement with the Supreme Council of the Arab–African Economy which has expressed an interest in providing necessary investments and partnerships to support the entry of Resverlogix's first–in–class drug "" apabetalone into the Arab–African Economy.

"We are excited to be collaborating with the Supreme Council of the Arab–African Economy under the leadership of His Excellency Dr. Hani Abu Zaid," said Donald J. McCaffrey, President & CEO of Resverlogix. "By entering into this cooperation agreement, it will assist our approach in strengthening our relationships, developments, and interests within the Arab–African Economy, while propelling the development of apabetalone," further commented Mr. McCaffrey.

"The Supreme Council of the Arab–African Economy is pleased to be in collaboration with Resverlogix to provide the necessary investment and assistance to support the emergence of apabetalone into the Arab–African Economy. We look forward to working with Mr. McCaffrey and his team of world–class scientists and experts in the field of epigenetics," stated His Excellency Dr. Hani Abu Zaid, President of the Supreme Council for the Arab–African Economy.

Resverlogix has been actively working with hospitals and the respective ministries globally to commence COVID–19 clinical trials. On October 12th, 2021 Resverlogix received ethics committee approval for Western Canadian sites in a Phase 2 clinical trial for apabetalone in COVID–19 patients. On November 1st, 2021 the Canadian arm of the trial began actively recruiting patients. Additionally, a Phase 3 COVID–19 trial in the US is anticipated to commence in coming months based on final protocol approval.

Phase 2 Trial Overview "" Canada/Brazil

Study participants will be made up of patients hospitalized with confirmed COVID–19 cases. Participants will either receive twice daily doses of apabetalone for up to 4 weeks alongside standard of care, compared to standard of care alone. The primary outcome measure of the study will be change in the World Health Organization (WHO) Ordinal Scale for Clinical Improvement. A total of 100 patients are expected to be enrolled at multiple sites in Canada and Brazil. The study is actively recruiting in the Canadian arm. The full study protocol can be found on clinicaltrials.gov.

About the Supreme Council of Arab–African Economy – The Council's Mandate

The Supreme Economic Council for the Arab–African Economy is an economic–diplomatic body recognized by the United Nations, European Union, Arab League, and the Common Market for Eastern and Southern Africa (COMESA). The Supreme Economic Council for the Arab–African Economy specializes in promoting and facilitating investments and trade in member nations and affiliates to strengthen their economies.

About Apabetalone

Apabetalone (RVX–208), is a first–in–class, epigenetic small molecule, or gene regulating, therapeutic candidate. It is a selective BET (bromodomain and extra–terminal) inhibitor, which works in preventing disease by turning genes on and/or off through regulation of gene expression. The prevalence of BET proteins in the human body allows apabetalone, through its unique mechanism of action, to simultaneously target multiple disease–causing biological processes while maintaining a well described safety profile "" leading to a new way to treat chronic disease.

Cardiology:

In February 2020, apabetalone became the first therapy of its kind to receive Breakthrough Therapy Designation by the US Food and Drug Administration (FDA) "" for a major cardiovascular indication "" following the ground–breaking findings from the BETonMACE Phase Three study. Data from BETonMACE showed apabetalone can potentially prevent major adverse cardiac events among high–risk cardiovascular disease patients who also have type 2 diabetes mellitus.

Covid–19:

On March 23, 2020, Resverlogix launched its COVID–19 program, enlisting world–renowned collaborators. Studies demonstrate that apabetalone has the potential to act against COVID–19 with a unique dual–mechanism: the first pillar of apabetalone's dual–mechanism is preventing viruses from entering the cells and replicating; the second pillar is averting runaway inflammatory reactions that can cause severe and lasting organ damage. A Phase 2 clinical trial is evaluating apabetalone in combination with standard of care for patients hospitalized with COVID–19. Apabetalone treatment could potentially reduce the severity and duration of COVID–19. Apabetalone's unique dual–mechanism also means that it is likely to show efficacy against COVID–19 variants and may even help fight other related viruses.

Apabetalone is the only drug of its class with a well–established safety record in human clinical trials, with well over 4200 patient–years on drug across 10 clinical trials.

About Resverlogix

Founded in 2001, Resverlogix is a Calgary based late–stage biotechnology company and the world leader in epigenetics, or gene regulation, with the goal of developing first–in–class therapies for the benefit of patients with chronic disease.

Resverlogix is commercializing a new class of epigenetic therapies designed to regulate gene expression, turning disease–associated genes "on" or "off". We aim to improve patients' lives by restoring biological functions "" altered by serious illnesses such as cardiovascular disease "" back to a healthier state.

The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease and associated comorbidities, and COVID–19.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

Follow us: Twitter: @Resverlogix_RVX.
LinkedIn: https://www.linkedin.com/company/resverlogix–corp–/

For further information please contact:

Investor Relations
Email: ir@resverlogix.com
Phone: 403–254–9252
www.resverlogix.com

Forward Looking Statements:

This news release may contain certain forward–looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. In particular, this news release includes forward looking information related to the Company's discussions with the Supreme Council of Arab–African Economy, the Company's clinical trials and the potential role of apabetalone in the treatment of patients with COVID–19 (and potentially other viruses), cardiovascular disease and associated comorbidities and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward–looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward–looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward–looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward–looking statements, whether as a result of new information, future events or otherwise.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/12958904–5b38–4a6a–8d1c–d11786bd9487


GLOBENEWSWIRE (Distribution ID 8387430)

Synchronoss Personal Cloud Solution Selected by Telkomsel to Bolster Digital Services Offering

BRIDGEWATER, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (NASDAQ: SNCR), a global leader and innovator of cloud, messaging and digital solutions, today announced it would supply its personal cloud solution to Telkomsel, Indonesia's largest mobile operator. The addition of the Synchronoss Personal Cloud solution will give Telkomsel's subscribers the ability to back up and manage their valuable digital content, including photos and videos, from any device.

The white–label Synchronoss Personal Cloud solution""branded "Floudrive" and managed by Telkomsigma""will be made available to Telkomsel's 170 million subscribers as a premium feature. Subscribers will be able to choose between two different storage tiers and enjoy an initial free 30–day period. The solution gives subscribers a reliable and intuitive cloud storage experience, with the ability to backup and sync digital content, while also introducing advanced tagging and search capabilities.

"We are excited to be partnering with Synchronoss to integrate its personal cloud solutions into our consumer channel," said Tanto Suratno, Director of Business and Sales, Telkomsigma. "Having outgrown our existing personal cloud offering, now is the perfect time to embrace this opportunity and provide our subscribers with an advanced solution that meets their evolving needs. We look forward to enabling our customers to optimize and manage their precious digital content, and to protect and store it safely and securely. As well as benefiting our customers, this partnership also represents the next step as we move towards offering more digital services."

The solution will be delivered through Synchronoss' agreement with Telkomsigma, the IT Services and Data Center arm of Telkomsel and Telkomsigma's parent company, Telkom Indonesia. Unlike other cloud solutions on the market, the Synchronoss–powered personal cloud allows subscriber data to be stored in–country, a critical requirement for Telkomsel to adhere to Indonesian law.

Anthony Socci, President and General Manager, APAC for Synchronoss, said he is delighted to be working with Telkomsel on its new cloud offering. "As a private cloud solution provider, we are always looking for ways to support telecom partners in their mission to deliver more varied and advanced digital services to their subscribers. This cloud solution will be instrumental to Telkomsel as it facilitates a more integrated experience and promotes a safer handling of personal assets," he said. "This deal builds on the success we have already experienced with Telkomsigma that impressed and inspired Telkomsel to deliver similar offerings to their mobile subscribers. It will also create greater synergies between the two organizations within the group."

To learn more about Synchronoss cloud solutions, visit synchronoss.com/solutions/cloud.

About Synchronoss
Synchronoss Technologies (NASDAQ: SNCR) builds software that empowers companies around the world to connect with their subscribers in trusted and meaningful ways. The company's collection of products helps streamline networks, simplify onboarding, and engage subscribers to unleash new revenue streams, reduce costs and increase speed to market. Hundreds of millions of subscribers trust Synchronoss products to stay in sync with the people, services and content they love. That's why more than 1,500 talented Synchronoss employees worldwide strive each day to reimagine a world in sync. Learn more at www.synchronoss.com.

Media Contacts

For Synchronoss:
Anais Merlin,
CCgroup,
E: synchronoss@ccgrouppr.com

Investor Contact
For Synchronoss: Todd Kehrli/Joo–Hun Kim, MKR Investor Relations, Inc., E: investor@synchronoss.com


GLOBENEWSWIRE (Distribution ID 8387224)

Bombardier Celebrates Graduation of First Cohort of Red Oak, Texas-based Apprentices in Comprehensive Training Program

  • Department of Labor (DOL) nationally accredited apprenticeship program allows Bombardier to attract talented individuals from across the U.S. to grow dedicated talent pool in Red Oak
  • Graduates of the program offered full–time employment to support development of Global 7500 advanced smooth flex wing at Red Oak facility
  • Program fuels local grassroots aerospace pipeline

RED OAK, Texas, Nov. 04, 2021 (GLOBE NEWSWIRE) — Bombardier today announced the graduation of 10 participants from its first cohort of apprentices enrolled in its comprehensive apprenticeship training program developed in association with Texas State Technical College (TSTC) in Red Oak, Texas. With the successful completion of the training program, graduates are offered full–time employment at Bombardier's Red Oak facility as an aircraft assembler or aerostructures apprentice to work on the Global 7500 business jet's advanced smooth flex wing.

The two–year Department of Labor (DOL) accredited Bombardier Aerospace Apprenticeship Program (BAAP), launched in December 2019, offers students the opportunity to enter the high–tech aerospace sector with no specific pre–requisites. It challenges them to present a winning attitude and develop mechanical dexterity and sound logic skills to pass an entry–level aptitude test. In turn, Bombardier and TSTC offer expert training in conjunction with TSTC's excellent facilities, allowing students to benefit at no cost from industry–tailored modules, experienced instructors, tools and equipment and financial support. Since its inception, some 80–plus individuals are currently being trained in the program. Bombardier and TSTC plan to recruit more than 50 individuals into the program over the next two years.

"I am thrilled to celebrate the successful graduation of the women and men in the BAAP program who will now transition forward in new careers at Bombardier, helping to ramp up the development of Bombardier's Global 7500 program," said Paul Sislian, Executive Vice President, Operations and Operational Excellence, Bombardier. "The accomplishments of these talented individuals aptly underscore the importance of fueling the aerospace pipeline in our Red Oak facility, bringing world–class training opportunities and cementing Bombardier as a key pillar of the community. It's a wonderful way for Bombardier to celebrate National Apprenticeship Week in the U.S."

The apprenticeship program offers a unique blend of practical and on–the–job training with theoretical, in–class learning. Educational topics covered include the introduction of health, safety and quality best practices, as well as aircraft drawing and specification comprehension, manufacturing appreciation of standard and regulatory compliances of aircraft assembly and more.

The Global 7500 jet is the flagship of the Bombardier business aircraft fleet, and it has won numerous awards for its innovative design. The Global 7500 aircraft's advanced smooth flex wing design features sophisticated slats and flap system that maximizes aerodynamic efficiency and performance for improved safety and an exceptionally smooth ride.

About Texas State Technical College
TSTC was established 50 years ago to help create a strong Texas. It is efficiently and effectively helping Texas meet the high–tech challenges of today's global economy, in partnership with business and industry, government agencies and other educational institutions. TSTC graduates are highly valued by business and industry for their work ethics, knowledge and workplace skills.

About Bombardier
Bombardier is a global leader in aviation, creating innovative and game–changing planes. Our products and services provide world–class experiences that set new standards in passenger comfort, energy efficiency, reliability and safety.

Headquartered in Montral, Canada, Bombardier is present in more than 12 countries including its production/engineering sites and its customer support network. The Corporation supports a worldwide fleet of over 4,900 aircraft in service with a wide variety of multinational corporations, charter and fractional ownership providers, governments and private individuals.

News and information is available at bombardier.com or follow us on Twitter @Bombardier.
Visit the Bombardier Business Aircraft website for more information on our industry–leading products and services.

Bombardier, Global and Global 7500 are registered or unregistered trademarks of Bombardier Inc. or its subsidiaries.

For information
Matthew Nicholls
Bombardier
+1 514–243–8214
Matthew.Nicholls@aero.bombardier.com


GLOBENEWSWIRE (Distribution ID 8387049)

Bombardier Names Nick W. Verdea Recipient of 2021 Safety Standdown Award

  • A long–time Safety Standdown supporter, Verdea has demonstrated exceptional safety leadership throughout his 25–year aviation career
  • Influential award recognizes exceptional efforts to improve aviation safety throughout the industry
  • Bombardier's Safety Standdown celebrating 25 years of aviation safety stewardship and education

MONTREAL, Nov. 04, 2021 (GLOBE NEWSWIRE) — Nick W. Verdea, a Certified Aviation Manager (CAM) and Global Leadership Professional (GLP), has been named the 2021 winner of the Bombardier Safety Standdown Award, as selected by the Safety Standdown Advisory Council members. Verdea, Director of Aviation and Corporate Travel for The Williams Company in Tulsa, OK., is a long–time supporter and advocate of this highly influential event.

Verdea accepted the award on November 3, 2021, during the 25th annual Bombardier Safety Standdown event in Wichita, KS. The two–day, in–person safety gathering brought industry professionals together for enhanced learning opportunities, compelling workshops, presentations and more, laying the foundation for safety training and professional development. For a quarter of a century, Bombardier has led the industry in providing aviation professionals with critical knowledge–based aviation training and lifelong professional development opportunities.

The Bombardier Safety Standdown Award is presented annually to an aviation professional who has demonstrated exemplary dedication to improving aviation safety through the Safety Standdown principles of Learn, Apply, Share. Verdea was nominated for his leadership in aviation safety management over the course of his 25–year aviation career by Richard Westmoreland, Director of Aviation for First Horizon. At The Williams Company, Verdea oversees the daily operations and priorities of a high–performing team of 13 that operates corporate aircraft. A major part of his responsibilities is to execute and expertly manage the annual travel services budget with a compliance concentration on travel experience and cost containment. Verdea's commitment to safety excellence is admirable and this is clearly reflected in his many leadership roles over his career. He is a dedicated life–long learner and has an impeccable flying record of more than 13,000 accident–free hours in the cockpit.

"On behalf of Bombardier, I wish to congratulate Nick Verdea for his outstanding career and unwavering commitment to Safety Standdown and to promoting aviation safety and professionalism at all levels of our industry for a quarter of a century," said longtime Bombardier executive, Andy Nureddin, who stewards the Safety Standdown program. "Nick embodies precisely what the Safety Standdown Award stands for: celebrating individuals who are role models in the field and have made a real difference day–to–day. He is the ideal ambassador for our Safety Standdown mission."

Bombardier's Safety Standdown is one of the most comprehensive safety conferences in the industry. This year's in–person event celebrated 25 years of safety stewardship and this year's theme, "Learn, Apply, Share" reminds aviation professionals and organizations to learn new skills, apply them and share their knowledge to make an impact as a role model.

About Safety Standdown
Conceived in 1996 as a human factors safety–training event for the Learjet flight demonstration team, the conference quickly garnered a reputation for excellence beyond Bombardier's customer base. In 1999, in response to growing interest within the industry, Bombardier opened the seminar to all pilots. In 2010, Safety Standdown expanded beyond the seminars into a year–round global human factors program offering online resources. Since 1996, more than 10,000 corporate, commercial and military aviation professionals have attended Safety Standdown seminars around the world, live and through the webcast, including in Brazil, Canada, China, Mexico, Switzerland and the USA.

About Bombardier
Bombardier is a global leader in aviation, creating innovative and game–changing planes. Our products and services provide world–class experiences that set new standards in passenger comfort, energy efficiency, reliability and safety.

Headquartered in Montral, Canada, Bombardier is present in more than 12 countries including its production/engineering sites and its customer support network. The Corporation supports a worldwide fleet of over 4,900 aircraft in service with a wide variety of multinational corporations, charter and fractional ownership providers, governments and private individuals.

News and information is available at bombardier.com or follow us on Twitter @Bombardier.

Visit the Bombardier Business Aircraft website for more information on our industry–leading products and services.

Bombardier and Learjet are registered or unregistered trademarks of Bombardier Inc. or its subsidiaries.

For information
Matthew Nicholls
Bombardier
+1 514–243–8214
Matthew.Nicholls@aero.bombardier.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5720955a–d603–48bb–8597–9964e5b499e2


GLOBENEWSWIRE (Distribution ID 8386863)

Sustainability necessary for the hotel industry

DUBAI, United Arab Emirates, Nov. 04, 2021 (GLOBE NEWSWIRE) — Barrows, the provider of hotel investment and advisory services for hotels in the Middle East and Africa is investing heavily in making the hotel industry more sustainable.

A location where many people come together are hotels and hotel resorts. It is not without reason that the hotel industry is known as a major consumer of energy and consumption of food and drinks. But also consider, for example, the disposal of waste. There is still a lot to gain and improve in the hotel industry. Barrows Hotel Enterprises focuses on making the industry more sustainable and takes this into account in the choice for construction and hotel operator.

Employees and hotel guests have an important role in sustainability. New processes are used by them every day. The social responsibility of the hotel operator is increasing and that is necessary according to Chairman Erwin Jager of Barrows Hotel Enterprises.

Hotel operators and investors fully support making the industry more sustainable. It's necessary, because one of the main drivers is the increased attention from the global society. “The hotel guest really pays attention to the sustainability of the hotels and we see that when they make a choice for the hotel booking,” said Erwin Jager of Barrows.

Hotel guests are also increasingly willing to pay more for the room and facilities if this benefits a more sustainable stay. The investment will therefore be able to be repaid sooner than was previously the case.

As a Hospitality Professional, we are closely involved in the triangle between developer, investor and hotel operator. We have developed a sustainable strategy that is easy to implement during the construction phase and that benefits the operational processes of the hotel operator. We really add value with these improvements even if the location is in Africa, Middle East or Asia.

Without a hotel operator there is no business model and therefore no cash flow. By focusing on sustainable elements that creates the link between building and company during the first phase, the company is much better able to meet the requirements of hotel guests when it comes to sustainable business processes.

“The use of an international quality mark therefore can give an enormous boost to the quality mark of the hotels and their management. Hotel guests really opt for this and are prepared to pay a higher room rate or an additional service charge”, said Erwin Jager of Barrows.

Barrows Hotel Enterprises internationally manages more than 10,000 hotel rooms in more than 10 countries. The company started in 2008 as a real estate investor in the residential market in Dubai. Since 2012, Barrows has changed its strategy and the company is fully focused on the fast–growing hotel industry in the Middle East and Africa.

For more information
media@barrowshotels.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1d802a33–b156–48f6–92c3–e5d72ed87f41


GLOBENEWSWIRE (Distribution ID 1000566261)

Vaccitech Announces Publication of Second Phase 1 Clinical Trial Results of ChAdOx1 Vaccine in Development for the MERS Coronavirus

The Phase 1 clinical trial was conducted by The King Abdullah International Medical Research Centre (KAIMRC), in the Kingdom of Saudi Arabia (KSA), in partnership with the University of Oxford. Vaccitech retains commercial rights to this vaccine.

The ChAdOx1 MERS vaccine candidate was generally well tolerated and induced both humoral and cellular immune responses, which continued through the six–month follow–up period.

Study published online in The Lancet Microbe (https://www.thelancet.com/journals/lanmic/article/PIIS2666–5247(21)00193–2/fulltext).

OXFORD, United Kingdom, Nov. 04, 2021 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC), a clinical–stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the publication in The Lancet Microbe of the first Phase 1 clinical trial conducted in the Middle East evaluating the safety and tolerability of the ChAdOx1 MERS (Middle Eastern Respiratory Syndrome) vaccine candidate. The study builds on the first Phase 1 clinical trial of ChAdOx1 MERS conducted in the United Kingdom and published in Lancet ID last year.

The Phase 1 trial is part of a collaboration between the University of Oxford's Jenner Institute and the King Abdullah International Medical Research Center (KAIMRC). It is the first vaccine clinical trial to be conducted within the Kingdom of Saudi Arabia. Vaccitech retains commercial rights to the vaccine.

"The high fatality rate of diagnosed MERS–CoV makes it one of the most dangerous coronaviruses communicable between humans," says Naif Alharbi, KAIMRC, DPhil, vaccinologist and co–principal investigator on the MERS vaccine trial. "Research into robust preventative measures for a virus with pandemic potential is a global health imperative. The completion of our trial is the latest achievement for KAIMRC's world–leading MERS research and supports advancing the ChAdOx1 MERS vaccine candidate into its next phase of development. This multi–partner experience has also set the stage for more MERS vaccine clinical development in KSA, improving both research and regulatory expertise."

Dame Sarah Gilbert Ph.D., co–founder of Vaccitech said, "This was the first phase I trial of any vaccine conducted in KSA, and it is fitting that it was a trial of a vaccine against MERS. The results provide further evidence on the tolerability and immunogenicity profile of this vaccine candidate and pave the way for its further development."

Tom Evans, M.D., Chief Scientific Officer of Vaccitech added, "These important trial results, collected by scientists at the Jenner and KAIMRC, have the potential to progress us toward a much–needed vaccine for MERS. Their publication also builds on the already extensive dataset which supports our ChAdOx platform for prophylactic, pandemic preparedness, and therapeutic uses."

Twenty–four healthy adult volunteers aged 18 to 50 years received one of three single doses of ChAdOx1 MERS (at dose levels of 5 x 109 viral particles (VP), 2.5 x 1010 VP and 5 x 1010 VP). The primary objective was to assess safety and tolerability. Secondary objectives included evaluation of cellular and humoral immunogenicity from baseline through six months. The trial showed that ChAdOx1 MERS was generally well tolerated with most adverse events either mild or moderate. The most common adverse event was headache (58% of volunteers) followed by muscle pain (54%). The vaccine candidate induced robust antibody and T cell immune responses in all volunteers. Antibodies peaked at day 28 and T cell responses peaked at day 14, both of which were maintained until the end of follow–up at six months. The results of the study support advancing the vaccine candidate into Phase 2 development.

There have been more than 2,500 cases of MERS reported globally to the World Health Organization (WHO), including 886 deaths. The MERS case fatality rate is 34%, an order of magnitude greater than the rate reported for the COVID–19 coronavirus, SARS–CoV–2. The WHO lists MERS–CoV as a priority pathogen for vaccine development due to its threat to global health security.

Notes to editors:

About the trial and KAIMRC

The trial took place at King Abdullah International Medical Research Center (KAIMRC) and King Abdulaziz Medical City (KAMC). Both are part of the Ministry of National Guard Health Affairs (Saudi NGHA). KAMC in Riyadh has been recognised as a distinguished healthcare provider in Saudi Arabia and the region, with a bed capacity of 1501, and commenced its operations in May 1983. Since then, it has continued expanding, while providing services for a rapidly growing patient population in all of its catchment areas. Recently KAIMRC and KAMC have received approval for a Phase 1 clinical trial unit from the national regulator (Saudi FDA).

About MERS

First identified in 2012 in Saudi Arabia, MERS is a viral respiratory illness caused by the highly pathogenic MERS coronavirus (MERS–CoV). MERS–CoV is likely a zoonotic bat virus, with the dromedary camel implicated as the major animal host for spread to humans. Human to human transmission via droplets and contact can occur, especially in nosocomial settings, which lack robust infection control practices. MERS–CoV leads to severe disease of the lower respiratory tract, with a high symptomatic case fatality rate of ~34%. More than 2,500 cases of MERS have now been reported from 27 countries, including 12 Eastern Mediterranean countries. Globally, as of June 2021, MERS has now been responsible for 886 deaths with eight new cases of MERS reported from January 1, 2021, to May 3, 2021, in Saudi Arabia and UAE.

About Vaccitech plc

Vaccitech is a clinical–stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company's proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the well–validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable tolerability profiles and without the ability to replicate in humans. The combination of a ChAdOx prime treatment with subsequent MVA boost has consistently generated significantly higher magnitudes of CD8+ T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs. Vaccitech co–invented a COVID–19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.

Forward Looking Statement
This press release contains forward–looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding: the Company's business plans and objectives, including the timing and advancement of the Company's programs, such as the clinical trial of ChAdOx1 MERS (VTP–500) and the continued development of ChAdOx1 MERS, the potential therapeutic effects and expected patient population of ChAdOx1 MERS and the Company's use of capital, expenses and other financial results. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue" and similar expressions are intended to identify forward–looking statements, although not all forward–looking statements contain these identifying words. Any forward–looking statements in this press release are based on management's current expectations and beliefs and are subject to numerous risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward–looking statements contained in this press release, including, without limitation: the success, cost and timing of the Company's product development activities and planned and ongoing clinical trials, the Company's ability to execute on its strategy, regulatory developments, the Company's ability to fund its operations and the impact that the current COVID–19 pandemic will have on the Company's clinical trials and preclinical studies and other risks identified in the Company's filings with the Securities and Exchange Commission (the "SEC"), including its Quarterly Report on Form 10–Q for the first quarter of 2021 and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward–looking statements, which speak only as of the date they are made. The Company expressly disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward–looking statements.

Media contacts:

Katja Stout, Scius Communications (EU)
Direct: +44 (0) 7789435990
Email: katja@sciuscommunications.com

Robert Flamm, Ph.D. / Harrison Wong (US)
Burns McClellan, Inc.
212–213–0006 ext. 364 / 316
Email: rflamm@burnsmc.com / hwong@burnsmc.com

Henry Hodge, Vaccitech
Email: henry.hodge@vaccitech.co.uk


GLOBENEWSWIRE (Distribution ID 8386469)